Candel Therapeutics Stock Performance

CADL Stock  USD 5.84  0.09  1.52%   
On a scale of 0 to 100, Candel Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 2.11, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Candel Therapeutics will likely underperform. Please check Candel Therapeutics' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Candel Therapeutics' price patterns will revert.

Risk-Adjusted Performance

Mild

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Candel Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite quite weak fundamental indicators, Candel Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(1.52)
Five Day Return
(6.71)
Year To Date Return
7.35
Ten Year Return
(16.57)
All Time Return
(16.57)
1
Will Candel Therapeutics Inc. stock reach all time highs in 2025 - 2025 Institutional Moves Short-Term Trading Alerts - newser.com
11/10/2025
2
Candel Therapeutics Issues Quarterly Earnings Results, Misses Estimates By 0.04 EPS
11/14/2025
3
Candel Therapeutics to Host Virtual RD Event on December 5, 2025
11/17/2025
4
Will Candel Therapeutics Inc. stock gain from strong economy - 2025 Price Targets High Accuracy Trade Alerts - newser.com
11/21/2025
5
Candel Therapeutics Shares Little Changed on Clinical-Stage Progress
12/08/2025
6
Disposition of 6000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.38 subject to Rule 16b-3
12/30/2025
7
Can Candel Therapeutics Inc. stock attract ESG capital inflows - 2025 Momentum Check Consistent Return Strategy Ideas - ulpravda.ru
01/08/2026
8
Acquisition by Barone Francesca of 232000 shares of Candel Therapeutics at 6.01 subject to Rule 16b-3
01/26/2026
Begin Period Cash Flow35.7 M
Total Cashflows From Investing Activities-16 K

Candel Therapeutics Relative Risk vs. Return Landscape

If you would invest  522.00  in Candel Therapeutics on November 2, 2025 and sell it today you would earn a total of  62.00  from holding Candel Therapeutics or generate 11.88% return on investment over 90 days. Candel Therapeutics is currently generating 0.2678% in daily expected returns and assumes 4.1589% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Candel, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Candel Therapeutics is expected to generate 5.56 times more return on investment than the market. However, the company is 5.56 times more volatile than its market benchmark. It trades about 0.06 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

Candel Therapeutics Target Price Odds to finish over Current Price

The tendency of Candel Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 5.84 90 days 5.84 
about 24.69
Based on a normal probability distribution, the odds of Candel Therapeutics to move above the current price in 90 days from now is about 24.69 (This Candel Therapeutics probability density function shows the probability of Candel Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.11 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Candel Therapeutics will likely underperform. Additionally Candel Therapeutics has an alpha of 0.1042, implying that it can generate a 0.1 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Candel Therapeutics Price Density   
       Price  

Predictive Modules for Candel Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Candel Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Candel Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.715.8710.03
Details
Intrinsic
Valuation
LowRealHigh
4.608.7612.92
Details
Naive
Forecast
LowNextHigh
1.715.8710.03
Details
3 Analysts
Consensus
LowTargetHigh
16.9518.6220.67
Details

Candel Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Candel Therapeutics is not an exception. The market had few large corrections towards the Candel Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Candel Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Candel Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.10
β
Beta against Dow Jones2.11
σ
Overall volatility
0.57
Ir
Information ratio 0.04

Candel Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Candel Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Candel Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Candel Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (55.18 M) with loss before overhead, payroll, taxes, and interest of (23.07 M).
Candel Therapeutics currently holds about 86.78 M in cash with (27.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0.
Candel Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 17.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Barone Francesca of 232000 shares of Candel Therapeutics at 6.01 subject to Rule 16b-3

Candel Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Candel Stock often depends not only on the future outlook of the current and potential Candel Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Candel Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding31.7 M
Cash And Short Term Investments102.7 M

Candel Therapeutics Fundamentals Growth

Candel Stock prices reflect investors' perceptions of the future prospects and financial health of Candel Therapeutics, and Candel Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Candel Stock performance.

About Candel Therapeutics Performance

By examining Candel Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Candel Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Candel Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.59)(0.62)
Return On Capital Employed(0.55)(0.58)
Return On Assets(0.59)(0.62)
Return On Equity(0.96)(1.00)

Things to note about Candel Therapeutics performance evaluation

Checking the ongoing alerts about Candel Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Candel Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Candel Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (55.18 M) with loss before overhead, payroll, taxes, and interest of (23.07 M).
Candel Therapeutics currently holds about 86.78 M in cash with (27.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0.
Candel Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 17.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Barone Francesca of 232000 shares of Candel Therapeutics at 6.01 subject to Rule 16b-3
Evaluating Candel Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Candel Therapeutics' stock performance include:
  • Analyzing Candel Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Candel Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Candel Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Candel Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Candel Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Candel Therapeutics' stock. These opinions can provide insight into Candel Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Candel Therapeutics' stock performance is not an exact science, and many factors can impact Candel Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. Projected growth potential of Candel fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Candel Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(0.56)
Revenue Per Share
0.001
Return On Assets
(0.43)
Return On Equity
(0.70)
Understanding Candel Therapeutics requires distinguishing between market price and book value, where the latter reflects Candel's accounting equity. The concept of intrinsic value—what Candel Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Candel Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Candel Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Candel Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Candel Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.